Bloom Energy SEC Filings

Alphabet Inc. (GOOGL) – Form 144 filing: The John L. Hennessy and Andrea J. Hennessy Revocable Trust has filed a notice of proposed sale under Rule 144.

• Securities: 400 Class C common shares.
• Estimated value: US$72,828 (based on market price at filing).
• Broker: UBS Financial Services, Inc., 11 Madison Ave, New York.
• Planned sale date: on or about 14 Jul 2025 via Nasdaq.
• Shares outstanding: 5.459 billion; proposed sale equals <0.00001 % of float.
• Origin of shares: stock-award grants received 25 Jun 2023 (85 sh) and 25 Aug 2023 (315 sh).
• Recent insider activity: the same trust sold 1,400 Class C shares over the past three months for total gross proceeds of roughly US$240,000.

The filing is a routine compliance disclosure allowing the trustee to execute a modest sale. Given the negligible size relative to Alphabet's market capitalization and daily trading volume, the transaction is unlikely to exert measurable market impact or signal strategic shifts. Investors may nevertheless track ongoing insider disposition trends for sentiment cues; however, no adverse information is asserted by the filer, and the representation confirms the absence of undisclosed material developments.

Bloom Energy Corporation (BE) has filed a Form 144 indicating a planned disposition of 10,000,000 Class A common shares. The shares are to be sold through Morgan Stanley & Co. LLC on or about 07/10/2025 on the NYSE. Based on the stated aggregate market value of $287.1 million, the implied price per share is approximately $28.71.

The proposed sale represents roughly 4.3% of Bloom Energy’s 232,228,606 shares outstanding, making it a sizeable transaction that could create near-term supply pressure in the equity market. The filer attests that no undisclosed material adverse information is known and that all Rule 144 conditions are met.

No prior sales during the last three months are reported, and the shares were originally acquired directly from the issuer on 10/23/2021 for cash. Aside from the sale details, the filing contains no financial performance metrics or strategic commentary.

Kazia Therapeutics Limited (NASDAQ: KZIA) has filed a Rule 424(b)(3) prospectus supplement dated 9 July 2025 to incorporate a newly furnished Form 6-K into its December 2 2024 prospectus. The supplement attaches a 6-K that contains a press release reporting first‐in-human preliminary efficacy data from the company’s ongoing Phase 1b study evaluating paxalisib + pembrolizumab + chemotherapy in metastatic triple-negative breast cancer (TNBC).

• Patient profile: 61-year-old woman with lung-localized metastatic TNBC.
• Day-21 outcome (end of cycle 1): >50 % reduction in total circulating tumor cells (CTCs) and comparable decline in CTC clusters; decrease in mesenchymal phenotype of residual CTCs.
• Clinical context: CTC clusters are 20–100× more efficient at establishing metastases than single CTCs; standard chemotherapy alone often increases CTC counts in early cycles, underscoring the significance of the observed rapid decline.
• Strategic significance: Data echo pre-clinical findings published in Molecular Cancer Therapeutics, suggesting mechanistic synergy of paxalisib with immunotherapy. Enrollment in the Phase 1b trial continues, with plans for serial CTC and immune-micro-environment monitoring.
• Capital markets context: The filing registers 95,111 ADSs (representing 47,555,560 ordinary shares). The ADSs last traded at US$6.825 on 8 July 2025.

Investors should note that results stem from a single patient and remain subject to the usual clinical-development, regulatory and marketplace risks highlighted in the company’s risk-factor disclosures.

United Parks & Resorts Inc. (PRKS) filed a Form 4 on 07/02/2025 disclosing an equity grant to non-executive director Aayushi Dalal. The filing covers a 06/30/2025 transaction in which the director acquired 108 common shares—comprising 54 restricted stock units (RSUs) and 54 deferred stock units (DSUs)—under the company’s 2017 Omnibus Incentive Plan. The award vests 100% immediately; DSU shares will be issued three months after the director’s separation from service.

• Transaction code: “A” (award/grant)
• Price reported: $47.33 per share (grant-date fair value)
• Post-grant beneficial ownership: 5,466 PRKS shares held directly
• Reporting person role: Independent Director (not an officer or 10% owner)

The grant is routine board compensation and increases Dalal’s direct stake by roughly 2% relative to her prior holdings, a modest but positive alignment signal. No derivative securities were reported, and there is no indication that the transaction is part of a Rule 10b5-1 trading plan. The filing does not disclose broader financial results or strategic developments; its relevance is limited to corporate governance and insider-ownership monitoring.

United Parks & Resorts Inc. (PRKS) filed a Form 4 on 07/02/2025 disclosing an equity grant to non-executive director Aayushi Dalal. The filing covers a 06/30/2025 transaction in which the director acquired 108 common shares—comprising 54 restricted stock units (RSUs) and 54 deferred stock units (DSUs)—under the company’s 2017 Omnibus Incentive Plan. The award vests 100% immediately; DSU shares will be issued three months after the director’s separation from service.

• Transaction code: “A” (award/grant)
• Price reported: $47.33 per share (grant-date fair value)
• Post-grant beneficial ownership: 5,466 PRKS shares held directly
• Reporting person role: Independent Director (not an officer or 10% owner)

The grant is routine board compensation and increases Dalal’s direct stake by roughly 2% relative to her prior holdings, a modest but positive alignment signal. No derivative securities were reported, and there is no indication that the transaction is part of a Rule 10b5-1 trading plan. The filing does not disclose broader financial results or strategic developments; its relevance is limited to corporate governance and insider-ownership monitoring.

United Parks & Resorts Inc. (PRKS) filed a Form 4 on 07/02/2025 disclosing an equity grant to non-executive director Aayushi Dalal. The filing covers a 06/30/2025 transaction in which the director acquired 108 common shares—comprising 54 restricted stock units (RSUs) and 54 deferred stock units (DSUs)—under the company’s 2017 Omnibus Incentive Plan. The award vests 100% immediately; DSU shares will be issued three months after the director’s separation from service.

• Transaction code: “A” (award/grant)
• Price reported: $47.33 per share (grant-date fair value)
• Post-grant beneficial ownership: 5,466 PRKS shares held directly
• Reporting person role: Independent Director (not an officer or 10% owner)

The grant is routine board compensation and increases Dalal’s direct stake by roughly 2% relative to her prior holdings, a modest but positive alignment signal. No derivative securities were reported, and there is no indication that the transaction is part of a Rule 10b5-1 trading plan. The filing does not disclose broader financial results or strategic developments; its relevance is limited to corporate governance and insider-ownership monitoring.

180 Life Sciences Corp. (ATNF) filed an amended Form 4 for director Ryan Lewis Smith dated June 30, 2025. The filing discloses an equity grant made on June 17, 2025 and subsequently adjusted on June 28, 2025 to fit within the company’s 2022 Equity Compensation Plan.

• Restricted stock: 102,181 common shares issued at no cost for board services. The shares vest 50% on December 17, 2025 and 50% on June 17, 2026. Following the grant, Smith directly owns 167,181 common shares.
• Stock options: 255,000 non-qualified options with a $0.929 exercise price, granted under the 2025 Option Incentive Plan. Vesting mirrors the restricted stock schedule (50% on 12/17/25, 50% on 06/17/26). The options cannot be exercised unless shareholders approve the 2025 plan; if approval is not secured, the options will be cancelled.
• Purpose of amendment: To reflect the Board and Compensation Committee’s retroactive adjustment of share counts on June 28, 2025 so the award would fit within the remaining share reserve of the Equity Plan.

The transaction represents routine director compensation. While it increases potential dilution by roughly 0.7% of ATNF’s ~52 million shares outstanding, it aligns the director’s incentives with shareholders. The contingent nature of the option grant (subject to shareholder approval) limits immediate dilution risk.